IL264030A - Soluble fibroblast tumor growth-promoting receptor 3 (SFGFR3) polypeptides and their uses - Google Patents

Soluble fibroblast tumor growth-promoting receptor 3 (SFGFR3) polypeptides and their uses

Info

Publication number
IL264030A
IL264030A IL264030A IL26403018A IL264030A IL 264030 A IL264030 A IL 264030A IL 264030 A IL264030 A IL 264030A IL 26403018 A IL26403018 A IL 26403018A IL 264030 A IL264030 A IL 264030A
Authority
IL
Israel
Prior art keywords
sfgfr3
polypeptides
growth factor
factor receptor
fibroblast growth
Prior art date
Application number
IL264030A
Other languages
English (en)
Hebrew (he)
Original Assignee
Inst Nat Sante Rech Med
Therachon Sas
Univ Nice Sophia Antipolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Therachon Sas, Univ Nice Sophia Antipolis filed Critical Inst Nat Sante Rech Med
Publication of IL264030A publication Critical patent/IL264030A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL264030A 2016-07-07 2018-12-30 Soluble fibroblast tumor growth-promoting receptor 3 (SFGFR3) polypeptides and their uses IL264030A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359607P 2016-07-07 2016-07-07
US201762467478P 2017-03-06 2017-03-06
PCT/EP2017/067119 WO2018007597A1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IL264030A true IL264030A (en) 2019-01-31

Family

ID=59381265

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264030A IL264030A (en) 2016-07-07 2018-12-30 Soluble fibroblast tumor growth-promoting receptor 3 (SFGFR3) polypeptides and their uses

Country Status (20)

Country Link
US (3) US10294289B2 (enExample)
EP (2) EP3481859B1 (enExample)
JP (2) JP7046903B2 (enExample)
KR (2) KR102432192B1 (enExample)
CN (1) CN109715658B (enExample)
AU (2) AU2017294551B2 (enExample)
BR (1) BR112019000257A2 (enExample)
CA (1) CA3029877C (enExample)
DK (1) DK3481859T3 (enExample)
ES (1) ES2912559T3 (enExample)
HU (1) HUE058734T2 (enExample)
IL (1) IL264030A (enExample)
MX (1) MX2018016257A (enExample)
PL (1) PL3481859T3 (enExample)
PT (1) PT3481859T (enExample)
RU (1) RU2751483C2 (enExample)
SG (1) SG11201900074WA (enExample)
SI (1) SI3481859T1 (enExample)
WO (1) WO2018007597A1 (enExample)
ZA (1) ZA201900507B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
EP3684394A1 (en) * 2017-09-20 2020-07-29 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
US11625937B2 (en) * 2020-04-06 2023-04-11 Toyota Motor Engineering & Manufacturing North America, Inc. Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN121537499B (zh) * 2026-01-22 2026-05-08 中国科学院苏州纳米技术与纳米仿生研究所 一种来源于人β防御素-3的仿生肽及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
WO1996041523A1 (en) 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgf9 as a specific ligand for fgfr3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20040109850A1 (en) 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
AU2005216547B2 (en) 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2549769T3 (es) * 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
CA2880013C (en) 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
BR112015001724A2 (pt) 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CA2972865A1 (en) 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
EP3684394A1 (en) 2017-09-20 2020-07-29 Pfizer Inc. Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides

Also Published As

Publication number Publication date
ES2912559T3 (es) 2022-05-26
US11697678B2 (en) 2023-07-11
EP3481859A1 (en) 2019-05-15
JP2022096660A (ja) 2022-06-29
PL3481859T3 (pl) 2022-07-11
SG11201900074WA (en) 2019-02-27
JP7046903B2 (ja) 2022-04-04
RU2751483C2 (ru) 2021-07-14
US10294289B2 (en) 2019-05-21
EP4122955A1 (en) 2023-01-25
JP7348980B2 (ja) 2023-09-21
HUE058734T2 (hu) 2022-09-28
RU2019100381A3 (enExample) 2020-11-23
EP3481859B1 (en) 2022-04-13
CN109715658B (zh) 2023-09-12
KR102432192B1 (ko) 2022-08-12
RU2019100381A (ru) 2020-08-11
ZA201900507B (en) 2023-04-26
CN109715658A (zh) 2019-05-03
SI3481859T1 (sl) 2022-07-29
KR20190037240A (ko) 2019-04-05
MX2018016257A (es) 2019-11-21
US11021528B2 (en) 2021-06-01
AU2022202906A1 (en) 2022-05-26
CA3029877A1 (en) 2018-01-11
WO2018007597A1 (en) 2018-01-11
AU2017294551B2 (en) 2022-03-03
US20210309718A1 (en) 2021-10-07
AU2017294551A1 (en) 2019-01-31
CA3029877C (en) 2023-07-25
US20180230197A1 (en) 2018-08-16
DK3481859T3 (da) 2022-04-25
JP2019527053A (ja) 2019-09-26
PT3481859T (pt) 2022-05-23
KR20220122762A (ko) 2022-09-02
US20200190162A1 (en) 2020-06-18
BR112019000257A2 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
ZA201900507B (en) Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
IL273327A (en) Chimeric polypeptides and their uses
IL281273A (en) Adapted 21–FGF polypeptides and their uses
SG11202006420TA (en) Transferrin receptor-binding polypeptides and uses thereof
IL275463A (en) TLR7/8 antagonists and their use
IL292692B1 (en) Mrgprx2 antagonists and their uses
IL273253A (en) Glucagon-like peptide-1 receptor agonists and their uses
IL280808A (en) OX40-binding polypeptides and their uses
IL272749A (en) Soluble interferon receptors and their uses
SMT202300299T1 (it) Nuovi polipeptidi e relativi usi medici
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
IL292693B1 (en) Mrgprx2 antagonists and their uses
IL274751A (en) ILDR2 antagonists and combinations thereof
GB201819200D0 (en) Polypeptide and uses thereof
LT3336196T (lt) Kviečių žymenys ir jų naudojimas
GB201707139D0 (en) Polypeptides
GB201812328D0 (en) Polypeptides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
HK40031554A (en) Soluble interferon receptors and uses thereof
HK40023936A (en) Glucagon-like peptide 1 receptor agonists and uses thereof
HK40050222A (en) Ox40-binding polypeptides and uses thereof
AU2017901183A0 (en) Polypeptides and uses thereof